Dr. Stefanovic is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2400 Pratt St
Durham, NC 27705Phone+1 919-684-8964Fax+1 919-684-5325
Summary
- Dr. Alexandra Stefanovic is an oncologist in Durham, NC and is affiliated with Duke University Hospital. She received her medical degree from University of Cologne Faculty of Medicine and has been in practice 18 years. She also speaks multiple languages, including German. She specializes in hematologic oncology and is experienced in hematologic malignancies, cellular therapy, and general / benign hematology.
Education & Training
- University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 2005 - 2008
- Allegheny Health Network Medical Education Consortium (AGH)Residency, Internal Medicine, 2002 - 2005
- Univ Cologne- Fac MedClass of 1999
Certifications & Licensure
- NC State Medical License 2017 - 2025
- FL State Medical License 2008 - 2018
- PA State Medical License 2002 - 2005
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment Start of enrollment: 2009 Feb 01
Publications & Presentations
PubMed
- 28 citationsHistiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.Ronald S. Go, Eric D. Jacobsen, Robert A. Baiocchi, Ilia Buhtoiarov, Erin Butler
Journal of the National Comprehensive Cancer Network. 2021-11-01 - 59 citationsPrimary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factorsSoley Bayraktar, Ulas Darda Bayraktar, Juan Carlos Ramos, Alexandra Stefanovic, Izidore S. Lossos
Journal of Neuro-Oncology. 2011-01-01 - 27 citationsPhase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.Kevin R. Kelly, Jonathan W. Friedberg, Steven I. Park, Kevin T. McDonagh, John Hayslip
Clinical Cancer Research. 2018-12-15
Professional Memberships
- Member
- Member
Other Languages
- German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: